Page 94 - 《中国药房》2025年23期
P. 94

系统评估不同抗凝剂(如肝素钠)的影响,也缺乏-20 ℃                              transportation:an overview[J]. Diagnosis (Berl),2019,6
          冻存或高温应激等极端温度条件下的稳定性验证数据。                                (1):39-43.
          后续研究会进一步扩大样品量,系统考察更多温度梯度                            [ 9 ]  LIPPI  G,VON  MEYER  A,CADAMURO  J,et  al.
          与抗凝条件的影响,并探索构建基于物联网技术的智能                                 PREDICT:a  checklist  for  preventing  preanalytical  diag‐
                                                                   nostic  errors  in  clinical  trials[J].  Clin  Chem  Lab  Med,
          化温度实时监控系统。这些改进有望推动形成更具普
                                                                   2020,58(4):518-526.
          适性的标准操作规范,为相关领域专业人员提供兼具科
                                                              [10]  MURPHY R F,BALIS F M,POPLACK D G. Stability of
          学性与实践指导意义的参考依据。
                                                                   5-fluorouracil in whole blood and plasma[J]. Clin Chem,
              综上,全血中的 5-FU 在室温条件下稳定性较差,
                                                                   1987,33(12):2299-2300.
          2~8 ℃冷藏时稳定性略有提升但仍会快速降解;添加                           [11]  LEE J J,BEUMER J H,CHU E. Therapeutic drug moni‐
          1%体积比的稳定剂可显著延长其冷藏保存时间。本研                                 toring of 5-fluorouracil[J]. Cancer Chemother Pharmacol,
          究制定了5-FU TDM临床采样转运标准化流程,创新性                              2016,78(3):447-464.
          地将稳定剂添加节点设置于样品接收环节(而非采血后立                           [12]  LI M,MINDT S,LÜCK A,et al. Drug monitoring detects
          即添加),在保证样品分析质量的前提下,更贴合临床采                                under- and overdosing in patients receiving 5-fluorouracil-
          血的实际操作条件,显著提升了临床实际操作的可行性。                                containing  chemotherapy-results  of  a  prospective,multi‐
            致谢:感谢浙江迪赛思诊断技术有限公司提供的                                  center  German  observational  study[J].  ESMO  Open,
          血浆稳定性数据支持。                                               2023,8(2):101201.
                                                              [13]  张娟,吴东媛,刘铎,等. 5-FU治疗药物监测现状及其与
              利益冲突声明:本文作者与该公司无任何经济利益
                                                                   结直肠癌化疗毒性相关性的研究进展[J]. 中国药房,
          关联或潜在利益冲突。
                                                                   2018,29(12):1724-1728.
          参考文献
                                                              [14]  李然,焦园园,刘颖,等 . 1 例卡培他滨致严重不良反应
          [ 1 ]  GLEWIS S,MICHAEL M,GURNEY H,et al. Feasibility
                                                                   患者的治疗药物监测[J]. 中国药物应用与监测,2015,12
               and population exposure of 5-fluorouracil using therapeu‐
                                                                  (6):354-356.
               tic drug monitoring (PREDICT-5FU):a multicentre clini‐
                                                              [15]  QIN W,WANG X X,CHEN W Q,et al. An in vitro ap‐
               cal trial[J]. Br J Clin Pharmacol,2025,91(7):1965-1974.
                                                                   proach to simulate the process of 5-fluorouracil degrada‐
          [ 2 ]  KALDATE R R,HAREGEWOIN A,GRIER C E,et al.         tion  with  dihydropyrimidine  dehydrogenase:the  process
               Modeling  the  5-fluorouracil  area  under  the  curve  versus   in accordance to the first-order kinetic reaction[J]. Xenobio-
               dose  relationship  to  develop  a  pharmacokinetic  dosing       tica,2021,51(1):24-30.
               algorithm for colorectal cancer patients receiving FOLFOX6  [16]  RADOVANOVIC  M,SCHNEIDER  J  J,MARTIN  J  H,
               [J]. Oncologist,2012,17(3):296-302.                 et al. Comparison between a single- and a multi-point cali‐
          [ 3 ]  BEUMER J H,CHU E,ALLEGRA C,et al. Therapeutic     bration method using LC-MS/MS for measurement of 5-
               drug monitoring in oncology:international association of   fluorouracil  in  human  plasma[J].  J  Mass  Spectrom  Adv
               therapeutic  drug  monitoring  and  clinical  toxicology  re-   Clin Lab,2024,33:31-37.
               commendations  for  5-fluorouracil  therapy[J].  Clin  Phar‐  [17]  GURJAR  M,PRIYAN  K A,ASIA  P,et  al.  Optimizing
               macol Ther,2019,105(3):598-613.                     cancer patient care with a robust assay for 5-fluorouracil
          [ 4 ]  佟志强,吴东媛,张娟,等. UPLC-MS/MS法同时测定人                    quantification  and  in  vitro  stability  in  human  blood  for
               血浆中 5-FU 及其代谢产物 5-FUH2的浓度及应用[J]. 中                  therapeutic drug monitoring[J]. Pract Lab Med,2024,40:
               国药房,2021,32(4):480-484.                             e00415.
          [ 5 ]  涂碎萍,李获,陈岷,等. LC-MS测定结直肠癌患者血浆                 [18]  范先煜,汪硕闻,范国荣. LC-MS/MS法同时检测人血浆
               中 5-氟尿嘧啶浓度[J]. 实用药物与临床,2018,21(9):                  中氟尿嘧啶、尿嘧啶和二氢尿嘧啶的浓度及其临床应用
               1047-1051.                                          [J]. 药学服务与研究,2021,21(1):12-18.
          [ 6 ]  封敬颖,边静,崔毅轩,等. 中空纤维离心超滤结合高效                   [19]  ANDO  M,WATANABE  N,SEIKE  R,et  al.  Quantifica‐
               液相色谱法测定5-氟尿嘧啶的血药浓度[J]. 中国医院药                        tion of gimeracil,tegafur,and 5-FU in human plasma via
               学杂志,2021,41(13):1305-1308.                          LC-MS/MS  with  a  simplified  pretreatment  using  flow-
          [ 7 ]  PLEBANI M,SCOTT S,SIMUNDIC A M,et al. New in‐     through  extraction[J].  J  Chromatogr  B  Analyt  Technol
               sights  in  preanalytical  quality[J].  Clin  Chem  Lab  Med,  Biomed Life Sci,2025,1251:124424.
               2025,63(9):1682-1692.                                        (收稿日期:2025-08-05  修回日期:2025-11-21)
          [ 8 ]  NYBO M,CADAMURO J,CORNES M P,et al. Sample                                       (编辑:胡晓霖)








          · 2968 ·    China Pharmacy  2025 Vol. 36  No. 23                            中国药房  2025年第36卷第23期
   89   90   91   92   93   94   95   96   97   98   99